Dec 2 (Reuters) - Mesoblast Ltd MSB.AX :
* U.S. FDA GRANTED FAST TRACK DESIGNATION FOR REMESTEMCEL-L IN TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19 INFECTION
Dec 2 (Reuters) - Mesoblast Ltd MSB.AX :
* U.S. FDA GRANTED FAST TRACK DESIGNATION FOR REMESTEMCEL-L IN TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19 INFECTION